Study finds no added benefit in doubling Tamiflu dose

05/30/2013 | HealthDay News

Doubling the dose of the antiviral drug Tamiflu, or oseltamivir, doesn't benefit patients with severe flu, a study in BMJ found. Researchers tracked 326 people with severe flu at 13 hospitals in Southeast Asia and found no differences in virus levels, death rates and other outcomes between patients who took a standard dose of oseltamivir and those who received a double dose.

View Full Article in:

HealthDay News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC